A Clinical Study to Evaluate the Safety and Efficacy of BCMA-GPRC5D CAR-T in Patients With Relapsed/Refractory Multiple Myeloma Who Received Three or More Lines of Therapy
Conditions
Interventions
- DRUG: Fludarabine + Cyclophosphamide + BCMA-GPRC5D CAR-T Cells
Sponsor
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
Collaborators